pharma news today glp-1 obesity drug What is the pipeline for future medications for obesity? The GLP-1 Revolution: How Next-Generation

Description

About 11% of the global eligible population of 1.3 billion people could be on obesity drugs by that time, especially as research suggests other potential benefits of obesity drugs in the treatment of other diseases, according to estimates published by Morgan Stanley Research earlier this year

10 Blocking the reward value of food may expose latent behavioral vulnerabilities in high-risk patients

While this can be an intended effect, it's important not to reduce your intake of essential daily nutrients

While INMDs product actually sucked and wouldnt even actually benefit at all from increased abdominoplasty rates, ESTAs product is quite good and we managed to get in before the market was fully aware